Search 

GLG Research partners with organizations seeking efficient, targeted connections to insight.

Our Healthcare Practice provides you with access to expert insights on issues affecting the pharmaceutical, biotechnology, medical device, and healthcare services sectors. GLG works with:

• 9 of the top 10 pharmaceutical and biotechnology companies
• More than 80,000 experts from across the entire healthcare industry including physicians, researchers, scientists, payors, and healthcare industry executives
• 7 out of the top 10 global medical equipment companies
• Over 300,000 experts from all sectors, including former C-level operating executives, ex-top-tier strategy consultants and thought leaders from around the world

GfK Bridgehead is a global strategic healthcare consultancy that specializes in pricing and reimbursement, opportunity assessment, market access strategy, health economics, transaction support, valuation and due diligence.

Preferred partner for many major companies in the pharmaceutical, medical device, diagnostic and financial sectors.

Respected for bringing payer insights into R&D, portfolio, business development, commercialization and lifecycle strategies.

Renowned for qualitative and quantitative research capabilties.

A truly global organization, able to draw upon the expertise of 500 healthcare experts in more than 100 countries.

HealthCare Royalty Partners is a global healthcare investment firm with $1.5 billion in assets under management. Launched in 2007 by Founding Managing Directors Gregory B. Brown, M.D., Todd C. Davis and Clarke B. Futch, HC Royalty specializes in making structured investments in commercial-stage healthcare companies and products. Our deep experience, broad and flexible investment platform and proven track record set HC Royalty apart from other firms.

We closed on our first fund, HealthCare Royalty Partners, L.P., in July 2008 with over $500 million in capital. At closing this represented one of the largest inaugural healthcare-focused funds ever raised. In December 2011, we closed the largest private equity fund dedicated to healthcare royalty investments, HealthCare Royalty Partners II, L.P. and an affiliated fund, with $1 billion in capital. Our world-class list of investors consists of public and corporate pension funds, financial institutions, insurance companies, funds-of-funds and university endowments.

Our broad-based internal team has deep investment skills, as well as financial, legal and operational expertise. Collectively, these individuals possess over 100 years of healthcare and financial experience specifically in principal investing, structured finance, healthcare industry senior management, Wall Street research, healthcare industry consulting, and scientific and clinical advisory work

Founded in 2007, HealthCare Royalty Partners is a global healthcare investment firm with over USD 1.5 billion of capital under management. The Firm specializes in structured financing solutions for the life sciences industry.

The Company is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company has two FDA approved products: DUEXIS® and RAYOS®.  DUEXIS®s is a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and famotidine in a single pill.  DUEXIS is indicated for the relief of signs and symptoms of rheumatoid arthritis (“RA”) and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications. In June 2012, the Company began expanding its commercial organization and expects to almost double its original field force size by the end of the third quarter of 2012, to approximately 150 field sales representatives. Also in June 2012, the Company engaged Mallinckrodt LLC, the pharmaceutical business of Covidien plc, on a non-exclusive basis to co-promote DUEXIS in the U.S. and entered into an exclusive collaboration, license and supply agreement with Grünenthal S.A. for the potential commercialization of DUEXIS in Latin America.

The Company’s second product, RAYOS®, known as LODOTRA® outside the U.S., is a proprietary delayed release formulation of low-dose prednisone that is currently marketed in Europe by its distribution partner, Mundipharma International Corporation Limited (“Mundipharma”), for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. In addition, the Company has granted to Mundipharma commercialization rights to LODOTRA in Asia and Latin America. On July 26, 2012, the FDA approved RAYOS for the treatment of a broad range of diseases, including RA, polymyalgia rheumatica (“PMR”), psoriatic arthritis (“PsA”), ankylosing spondylitis (“AS”), asthma and chronic obstructive pulmonary disease (“COPD”). The Company anticipates the launch of RAYOS in the United States in the fourth quarter of 2012. The Company’s strategy is to commercialize its products in the U.S. and to enter into licensing or additional distribution agreements for commercialization of its products outside the U.S.

ImmunGene is leveraging promising science to empower therapeutic antibodies with immune molecules.  These molecules are highly optimized for dramatic efficacy and a superior safety profile. 

Our technology allows us to genetically engineer cytotoxic cytokines to antibodies to selectively target disease causing cells and tissues while reducing the systemic toxicity of the cytokines.  ImmunGene has several antibody molecules genetically engineered with interferon for following indications:

Non-Hodgkins lymphoma

Leukemia

Multiple myeloma

Melanoma

Renal cancer

Prostate cancer

Breast Cancer

Jaleva Pharmaceuticals is a company focused on the improved delivery of active ingredients to the skin or mucosa.  We achieve this with our Patented Resin technology, and do so topically, and transmucosally.  The core of our Delivery is fast acting, and long lasting delivery of API's.

We currently have three products ready for license.  

1. A Surgical Prep product to compete with Chloraprep.

2. A Topical Pain Relief Spray, for two times a day use.

3. An NRT Trans-buccal product, quick acting, mimicking the craving reduction of a cigarette.

We have an array of other products in our development pipeline.  

JRX Biotech is focused on (1) pain management and (2) dermatology applications.  We are a post revenue specialty biochemistry technology company.

We develop topical products using our patented delivery system platform (formfactors: liquid solutions, serums, lotions, creams, sprays).

DermX Megasphere Delivery System -- a dermal/transdermal delivery system technology platform that has been independently proven to allow high payloads of large molecular weight molecules to passively penetrate into and through human skin.

DermX Features / Benefits:

  --Passive, topical solution

  --Patented

  --Proven (Franz Cell and in vivo)

  --High payloads delivered (>20% of the applied dose penetrating)

  --Large molecules delivered (>11kD)

  --No irritation

We are looking to:

  (1) Co-develop our lead topical pain relief patented product (first-in-class).

  (2) Co-develop our pipeline of patented topical pain relief products.

  (3) Out-license our platform delivery system technology.